Connection

Pilar Escribano Subías to Receptors, Epoprostenol

Back to Details
This is a "connection" page, showing publications Pilar Escribano Subías has written about Receptors, Epoprostenol.
Pilar Escribano Subías
Connection Strength
0.211
Receptors, Epoprostenol
  1. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4).
    View in: PubMed
    Score: 0.211
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.